CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
WO2002043731A2
(fr)
|
2000-11-30 |
2002-06-06 |
University Of Florida |
Traitements de troubles neurogenetiques, de troubles du controle des impulsions, et cicatrisation des lesions
|
MEP59808A
(en)
*
|
2001-02-24 |
2011-05-10 |
Boehringer Ingelheim Pharma |
Xanthine derivative, production and use thereof as a medicament
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
JP4590159B2
(ja)
*
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法
|
HUP0600232A2
(en)
*
|
2001-04-11 |
2006-08-28 |
Bristol Myers Squibb Co |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CA2500873C
(fr)
|
2002-10-04 |
2012-01-17 |
Kissei Pharmaceutical Co., Ltd. |
Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
CN100391963C
(zh)
*
|
2003-01-03 |
2008-06-04 |
布里斯托尔-迈尔斯斯奎布公司 |
制备c-芳基葡糖苷sglt2抑制剂的方法
|
EP1457206A1
(fr)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
|
TWI309980B
(en)
|
2003-03-14 |
2009-05-21 |
Yamanouchi Pharma Co Ltd |
C-glycoside derivatives or salts thereof
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
CN103819465A
(zh)
*
|
2003-08-01 |
2014-05-28 |
田边三菱制药株式会社 |
新颖化合物
|
EP1680414A4
(fr)
*
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
Indazoles- glucosides substitues
|
AU2004261663A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
|
US8785403B2
(en)
*
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
EP1679965A4
(fr)
*
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
C-glycosides heterocycliques fusionnes substitues
|
WO2005012243A2
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Indole-o-glucosides substitues
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
JP5078350B2
(ja)
*
|
2004-03-04 |
2012-11-21 |
キッセイ薬品工業株式会社 |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
BRPI0508830B8
(pt)
|
2004-03-16 |
2021-05-25 |
Boehringer Ingelheim Int |
derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
|
DE602005025755D1
(de)
|
2004-06-04 |
2011-02-17 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
WO2006035796A1
(fr)
*
|
2004-09-29 |
2006-04-06 |
Kissei Pharmaceutical Co., Ltd. |
COMPOSÉ HÉTÉROCYCLIQUE AZOTÉ 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUÉ, PRÉPARATION THÉRAPEUTIQUE CONTENANT LEDIT COMPOSÉ, ET EMPLOI MÉDICAL DUDIT COMPOSÉ
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CA2582464A1
(fr)
*
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Modulation antisens de l'expression de ptp1b
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
ES2314743T3
(es)
*
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
TWI365186B
(en)
*
|
2005-01-31 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
ATE421518T1
(de)
*
|
2005-02-10 |
2009-02-15 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
DE602006009772D1
(de)
*
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
|
EP1874787B1
(fr)
*
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(fr)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
TW200733966A
(en)
*
|
2005-07-27 |
2007-09-16 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
ATE484499T1
(de)
*
|
2005-08-30 |
2010-10-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
AU2006289093A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
JP5094416B2
(ja)
*
|
2005-12-28 |
2012-12-12 |
武田薬品工業株式会社 |
糖尿病治療剤
|
JP2009531291A
(ja)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
CA2810839A1
(fr)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Polymorphes
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
US20090176717A1
(en)
*
|
2006-06-01 |
2009-07-09 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
PL2066344T3
(pl)
*
|
2006-09-07 |
2011-10-31 |
Glaxosmithkline Biologicals Sa |
Skojarzona szczepionka zawierająca inaktywowany wirus polio
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
JPWO2008044762A1
(ja)
|
2006-10-13 |
2010-02-18 |
中外製薬株式会社 |
チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用
|
JP2010507629A
(ja)
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
|
ES2397664T3
(es)
*
|
2006-12-04 |
2013-03-08 |
Janssen Pharmaceutica, N.V. |
Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
WO2008070692A2
(fr)
|
2006-12-06 |
2008-06-12 |
Smithkline Beecham Corporation |
Composés chimiques et leurs utilisations
|
US8198464B2
(en)
|
2006-12-21 |
2012-06-12 |
Astellas Pharma Inc. |
Method for producing C-glycoside derivative and intermediate for synthesis thereof
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008109591A1
(fr)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
PT2183263E
(pt)
*
|
2007-07-26 |
2012-01-11 |
Lexicon Pharmaceuticals Inc |
Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
|
CL2008002427A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
PE20090603A1
(es)
*
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
CN101784278A
(zh)
*
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
AU2008288770B2
(en)
*
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
PT2200606T
(pt)
*
|
2007-09-10 |
2017-12-13 |
Janssen Pharmaceutica Nv |
Processo para a preparação de compostos úteis como inibidores de sglt
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びcns障害の治療のためのpde9aモジュレーターとしてのそれらの使用
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
JP5302900B2
(ja)
*
|
2008-01-31 |
2013-10-02 |
アステラス製薬株式会社 |
脂肪性肝疾患の治療用医薬組成物
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
WO2009143021A1
(fr)
*
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Procédé pour traiter et prévenir des calculs rénaux à l'aide d'un inhibiteur de sglt2 et composition le contenant
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
CA2725047A1
(fr)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Procede de traitement de l'hyperuricemie a l'aide d'un inhibiteur de sglt2 et composition le contenant
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP2810951B1
(fr)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
BRPI0916769A2
(pt)
*
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
derivados de benzilbenzeno deuterados e métodos de uso
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
MX370599B
(es)
*
|
2008-08-15 |
2019-12-18 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
HUE029970T2
(en)
|
2008-08-22 |
2017-04-28 |
Theracos Sub Llc |
Method for producing SGLT2 inhibitors
|
RS52236B
(en)
*
|
2008-08-28 |
2012-10-31 |
Pfizer Inc. |
DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
|
NZ590788A
(en)
|
2008-09-08 |
2012-11-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of cns disorders
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
EP2342187A1
(fr)
*
|
2008-09-19 |
2011-07-13 |
Novartis AG |
Dérivés de glycosides et leurs utilisations
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
WO2010045656A2
(fr)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Nouvelles formes posologiques d'inhibiteur sglt2
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
SG173619A1
(en)
*
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
EP2395968B1
(fr)
*
|
2009-02-13 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Composition pharmaceutique contenant des dérivés de glucopyranosyl diphényl-méthane, sa forme posologique galénique, son procédé de préparation et ses utilisations pour une régulation glycémique améliorée chez un patient
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
JP5896276B2
(ja)
|
2009-02-13 |
2016-03-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1型糖尿病、2型糖尿病、耐糖能障害又は高血糖の治療用sglt−2阻害薬
|
MX2011008839A
(es)
*
|
2009-02-23 |
2011-09-28 |
Taisho Pharmaceutical Co Ltd |
Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1.
|
EP2226076A1
(fr)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Support d'enregistrement thermosensible et procédé d'enregistrement
|
MX2011010184A
(es)
*
|
2009-03-31 |
2011-10-28 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a.
|
EP2435033A1
(fr)
*
|
2009-05-27 |
2012-04-04 |
Bristol-Myers Squibb Company |
Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
WO2011003976A1
(fr)
|
2009-07-10 |
2011-01-13 |
Janssen Pharmaceutica Nv |
Procédé de cristallisation pour obtenir du 1-(β-d-glucopyranosyle)-4-méthyl-3-[5-(4-fluorophényle)-2-thiénylméthyle] benzène
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
BR112012007085B8
(pt)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
|
HUE029381T2
(en)
*
|
2009-09-30 |
2017-02-28 |
Boehringer Ingelheim Int |
A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene.
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
CA2777528C
(fr)
*
|
2009-10-14 |
2018-09-18 |
Janssen Pharmaceutica Nv |
Procede de preparation de composes utiles comme inhibiteurs de sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
ES2527179T3
(es)
|
2009-11-02 |
2015-01-21 |
Pfizer Inc. |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
WO2011060256A2
(fr)
*
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Formulations de comprimé bicouche
|
CA2779088A1
(fr)
|
2009-11-16 |
2011-05-19 |
Mellitech |
Derives de [1,5]-diazocine
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
WO2011070592A2
(fr)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Nouveaux dérivés de sucres
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
JP2013523681A
(ja)
*
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
CN105769792A
(zh)
|
2010-05-11 |
2016-07-20 |
田边三菱制药株式会社 |
含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂
|
WO2011143296A1
(fr)
|
2010-05-11 |
2011-11-17 |
Janssen Pharmaceutica Nv |
Formulations pharmaceutiques comprenant des dérivés de 1-(bêta-d-glucopyranosyl)-2-thiénylméthylbenzène comme inhibiteur de sglt
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
CA2803504C
(fr)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
Une combinaison destinee a la therapie du diabete renfermant une linagliptine une insuline a action lente
|
CN105541849B
(zh)
|
2010-08-12 |
2018-03-23 |
勃林格殷格翰国际有限公司 |
6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
|
WO2012025857A1
(fr)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
|
EP2611442B1
(fr)
|
2010-09-03 |
2018-07-04 |
Bristol-Myers Squibb Company |
Formulations de médicament au moyen d'antioxydants hydrosolubles
|
WO2012037034A1
(fr)
|
2010-09-14 |
2012-03-22 |
Glycomimetics, Inc. |
Antagonistes de l'e-sélectine
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(fr)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
JP2014504639A
(ja)
|
2011-02-01 |
2014-02-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
アミン化合物を含む医薬製剤
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
EP2676965B1
(fr)
|
2011-02-18 |
2017-10-04 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Composé aryl glycoside, son procédé de préparation et d'utilisation
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
PL2697218T3
(pl)
|
2011-04-13 |
2016-11-30 |
|
Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2
|
KR101609859B1
(ko)
*
|
2011-04-25 |
2016-04-07 |
베이징 프릴루드 팜. 에스씨아이. & 테크. 씨오., 엘티디. |
소듐-의존적 포도당 운반 단백질의 억제제 및 이의 제조방법 및 용도
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
WO2012160218A1
(fr)
*
|
2011-05-26 |
2012-11-29 |
Tfchem |
Famille de carbasucres aryliques, hétéroaryliques, o-aryliques et o-hétéroaryliques
|
EP2529742B1
(fr)
|
2011-06-03 |
2013-11-20 |
ratiopharm GmbH |
Composition pharmaceutique comportant de la dapagliflozine et cyclodextrine
|
CA2837232A1
(fr)
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Composition pharmaceutique comprenant de la dapagliflozine et de la cyclodextrine
|
CA2837627A1
(fr)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Inhibiteurs de sglt-2 pour traiter des troubles metaboliques chez des patients traites avec des agents neuroleptiques
|
WO2013000275A1
(fr)
|
2011-06-25 |
2013-01-03 |
山东轩竹医药科技有限公司 |
Dérivés de c-glycosides
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
JP2014530186A
(ja)
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
WO2013064909A2
(fr)
*
|
2011-10-31 |
2013-05-10 |
Scinopharm Taiwan, Ltd. |
Formes cristallines et non cristallines d'inhibiteurs de sglt2
|
EP2597090A1
(fr)
*
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Hydrate de dapagliflozine cristalline
|
CA2858099C
(fr)
|
2011-12-22 |
2020-12-15 |
Glycomimetics, Inc. |
Composes antagonistes de la selectine e, compositions et methodes d'utilisation
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP2849755A1
(fr)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
CN103450214B
(zh)
*
|
2012-05-29 |
2016-04-06 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP3549587A1
(fr)
|
2012-06-30 |
2019-10-09 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
IN2015DN01975A
(fr)
*
|
2012-08-30 |
2015-08-14 |
Taisho Pharmaceutical Co Ltd |
|
DK2928476T3
(en)
|
2012-12-07 |
2018-05-22 |
Glycomimetics Inc |
RELATIONSHIPS, COMPOSITIONS AND METHODS OF USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(fr)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
EP3466431B1
(fr)
|
2013-03-14 |
2023-11-15 |
MSD International GmbH |
Formes crystallins et modes preparatoires pour la manufacture des inhibiteurs de sglt2
|
CA2905438A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
WO2014161836A1
(fr)
|
2013-04-04 |
2014-10-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Traitement de troubles métaboliques chez des équidés
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2014170383A1
(fr)
|
2013-04-18 |
2014-10-23 |
Boehringer Ingelheim International Gmbh |
Composition pharmaceutique, procédés de traitement et leurs utilisations
|
EP2991999B1
(fr)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Co-cristal de dapagliflozine et de lactose
|
PT3004138T
(pt)
|
2013-06-05 |
2024-06-18 |
Bausch Health Ireland Ltd |
Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
|
WO2015040571A1
(fr)
|
2013-09-23 |
2015-03-26 |
Ranbaxy Laboratories Limited |
Méthode de préparation de dapagliflozine
|
JP6450769B2
(ja)
|
2013-09-27 |
2019-01-09 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
グルコピラノシル誘導体及びその医薬品における使用
|
US20160237054A1
(en)
*
|
2013-09-27 |
2016-08-18 |
Sun Pharmaceutical Industries Limited |
Process for the purification of dapagliflozin
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
US20160280619A1
(en)
*
|
2013-10-31 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
EP3862003B1
(fr)
|
2013-12-17 |
2023-10-25 |
Boehringer Ingelheim Vetmedica GmbH |
Un inhibiteur de sglt-2 pour le traitement des troubles métaboliques chez les félins
|
WO2015101916A1
(fr)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Procédé pour la préparation d'empagliflozin
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
PL3096765T3
(pl)
|
2014-01-23 |
2019-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt psowatych
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(fr)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
EP3110402A1
(fr)
|
2014-02-28 |
2017-01-04 |
Sun Pharmaceutical Industries Ltd |
Compositions de dapagliflozin
|
EP3114115A4
(fr)
*
|
2014-03-06 |
2017-08-23 |
MSN Laboratories Private Limited |
Procédé pour la préparation de (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-éthoxyphényl)méthyl]phényl]-d-glucitol et de son solvate
|
MX2016012705A
(es)
|
2014-04-01 |
2016-12-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabolicos en animales equinos.
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP2944311A1
(fr)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
|
EP3142661B1
(fr)
*
|
2014-05-16 |
2021-10-06 |
Astrazeneca AB |
Méthode de suppression de la sécrétion de glucagon d'un inhibiteur de sglt2
|
WO2015198227A1
(fr)
|
2014-06-23 |
2015-12-30 |
Sun Pharmaceutical Industries Limited |
Co-cristal de dapagliflozin et d'acide citrique
|
AU2015323779B2
(en)
|
2014-09-25 |
2018-08-09 |
Astrazeneca Ab |
Combination of an omega-3 fatty acid and an SGLT-2 inhibitor for treating diseases of the liver
|
BR112017003570A2
(pt)
|
2014-09-25 |
2017-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
tratamento de combinação de inibidores de sglt2 e agonistas de dopamina para prevenir distúrbios metabólicos em animais equinos
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
DK3227310T3
(da)
|
2014-12-03 |
2019-09-30 |
Glycomimetics Inc |
Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
EP3256482B1
(fr)
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Procédé de préparation de composés inhibiteurs de sglt
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
WO2016161995A1
(fr)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Formes solides de dapagliflozine amorphe
|
WO2016178148A1
(fr)
*
|
2015-05-05 |
2016-11-10 |
Glenmark Pharmaceuticals Limited |
Procédé de préparation de dapagliflozine
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
EP3349762B1
(fr)
|
2015-09-15 |
2021-08-25 |
Laurus Labs Limited |
Co-cristaux d'inhibiteurs de sglt2, procédé pour leur préparation et compositions pharmaceutiques de ceux-ci
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのsglt−2阻害剤
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
UA122083C2
(uk)
*
|
2016-01-04 |
2020-09-10 |
Че Іль Фармасьютікал Ко., Лтд. |
C-глікозидні похідні, які містять конденсоване фенільне кільце, або їхні фармацевтично прийнятні солі, спосіб одержання таких і фармацевтична композиція, що містить такі
|
WO2017118945A1
(fr)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Prémélange de dapagliflozine et son procédé de préparation
|
WO2017127422A1
(fr)
|
2016-01-22 |
2017-07-27 |
Glycomimetics, Inc. |
Inhibiteurs glycomimétiques des lectines pa-il et pa-iil
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
JP2019512537A
(ja)
|
2016-03-31 |
2019-05-16 |
ルピン・リミテッド |
ダパグリフロジンの医薬組成物
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
EP3466939B1
(fr)
*
|
2016-05-24 |
2021-02-24 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Nouvelle forme cristalline de la dapagliflozine, son procédé de préparation et son utilisation
|
WO2017203229A1
(fr)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Prémélanges de dapagliflozine
|
WO2017211979A1
(fr)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinaisons de linagliptine et de metformine
|
WO2018002673A1
(fr)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
|
US11433086B2
(en)
|
2016-08-08 |
2022-09-06 |
Glycomimetics, Inc. |
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
|
ES2926403T3
(es)
*
|
2016-08-09 |
2022-10-25 |
Laurus Labs Ltd |
Nuevos procedimientos para la preparación de dapagliflozina o sus solvatos o co-cristales de la misma
|
WO2018029264A1
(fr)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Procédé de préparation de dapagliflozine et de ses intermédiaires
|
WO2018068010A1
(fr)
|
2016-10-07 |
2018-04-12 |
Glycomimetics, Inc. |
Antagonistes de e-sélectine multimériques très puissants
|
EP3528800A1
(fr)
|
2016-10-19 |
2019-08-28 |
Boehringer Ingelheim International GmbH |
Combinaisons comprenant un inhibiteur de ssao/vap-1 et un inhibiteur de sglt2, leurs utilisations
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(fr)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Procédé de préparation de dapagliflozine
|
EP3596096A1
(fr)
|
2017-03-15 |
2020-01-22 |
GlycoMimetics, Inc. |
Dérivés de galactopyranosyle-cyclohexyle utilisés en tant qu'antagonistes d'e-sélectine
|
US11020412B2
(en)
|
2017-03-16 |
2021-06-01 |
Inventia Healthcare Limited |
Pharmaceutical composition comprising dapagliflozin
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのPPARγアゴニスト
|
US11312740B2
(en)
|
2017-05-09 |
2022-04-26 |
Piramal Pharma Limited |
Process for the preparation of SGLT2 inhibitors and intermediates thereof
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
WO2019108750A1
(fr)
|
2017-11-30 |
2019-06-06 |
Glycomimetics, Inc. |
Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
|
AU2018395417B2
(en)
|
2017-12-29 |
2023-07-13 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
CA3091454A1
(fr)
|
2018-03-05 |
2019-09-12 |
Glycomimetics, Inc. |
Methodes de traitement de la leucemie aigue myeloide et d'etats pathologiques associes
|
JP2021520394A
(ja)
|
2018-04-17 |
2021-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、処置方法及びその使用
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(fr)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
Nouveau procédé de préparation d'inhibiteurs de sglt-2
|
EP3823631A1
(fr)
*
|
2018-07-19 |
2021-05-26 |
Astrazeneca AB |
Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
WO2020039394A1
(fr)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
Nouvelles combinaisons de médicaments
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
PE20211267A1
(es)
|
2019-08-30 |
2021-07-19 |
Astrazeneca Ab |
Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
|
EP4064854A1
(fr)
*
|
2019-11-28 |
2022-10-05 |
Boehringer Ingelheim Vetmedica GmbH |
Utilisation d'inhibiteurs de sglt-2 dans le séchage de mammifères non humains
|
MX2022010090A
(es)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
|
CA3169665A1
(fr)
|
2020-02-21 |
2021-08-26 |
Zaklady Farmaceutyczne Polpharma S.A. |
Composition pharmaceutique comprenant de la dapagliflozine
|
EP4114365A1
(fr)
|
2020-03-05 |
2023-01-11 |
KRKA, d.d., Novo mesto |
Composition pharmaceutique comprenant un inhibiteur du sglt2
|
BR112022017189A2
(pt)
|
2020-03-06 |
2022-10-18 |
Vertex Pharma |
Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
|
EP4138826A1
(fr)
|
2020-04-22 |
2023-03-01 |
Bayer Aktiengesellschaft |
Combinaison de finérénone et d'un inhibiteur de sglt2 pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou rénales
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
CN115867538A
(zh)
|
2020-06-05 |
2023-03-28 |
新梅斯托克公司 |
高纯的无定形达格列净的制备
|
WO2021260617A1
(fr)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
|
WO2022009163A1
(fr)
|
2020-07-10 |
2022-01-13 |
Astrazeneca Ab |
Combinaison de zibotentan et de dapagliflozine pour le traitement d'une maladie rénale chronique
|
WO2022022865A1
(fr)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Procédés de traitement d'une maladie rénale chronique avec de la dapagliflozine
|
WO2022051316A1
(fr)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
|
WO2022067724A1
(fr)
|
2020-09-30 |
2022-04-07 |
北京睿创康泰医药研究院有限公司 |
Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
WO2022119543A1
(fr)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
EP4315350A1
(fr)
|
2021-04-01 |
2024-02-07 |
AstraZeneca UK Limited |
Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine
|
EP4079296A1
(fr)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
EP4376819A1
(fr)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
|
US20240307426A1
(en)
|
2021-07-28 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
MX2024001184A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
IL314031A
(en)
|
2021-12-30 |
2024-09-01 |
Newamsterdam Pharma B V |
Materials and methods for improved phosphotransferases
|
EP4212150A1
(fr)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|
WO2023227492A1
(fr)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Compositions pharmaceutiques aqueuses comprenant des inhibiteurs de sglt-2
|
TW202415364A
(zh)
|
2022-06-07 |
2024-04-16 |
瑞典商阿斯特捷利康公司 |
Rxfp1調節劑和sglt2抑制劑之組合
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|
WO2024166009A1
(fr)
|
2023-02-08 |
2024-08-15 |
Astrazeneca Ab |
Combinaison de zibotentan et de dapagliflozine pour le traitement d'une maladie rénale chronique à haute protéinurie
|
EP4431088A1
(fr)
|
2023-03-06 |
2024-09-18 |
Galenicum Health S.L.U. |
Compositions pharmaceutiques comprenant de la dapagliflozine et de la metformine
|
EP4427742A1
(fr)
|
2023-03-06 |
2024-09-11 |
Galenicum Health S.L.U. |
Compositions pharmaceutiques comprenant de la dapagliflozine et de la metformine
|
WO2024184293A1
(fr)
|
2023-03-06 |
2024-09-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Systèmes d'administration de compositions pharmaceutiques liquides comprenant en particulier un ou plusieurs inhibiteurs de sglt-2
|